Phathom Pharmaceuticals Inc (PHAT)’s debt-to-equity and long-term debt/equity ratios

As of close of business last night, Phathom Pharmaceuticals Inc’s stock clocked out at $10.60, down -0.19% from its previous closing price of $10.62. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 729065 shares were traded.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.



To gain a deeper understanding of PHAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.22 and its Current Ratio is at 10.25.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 05, 2024, Reiterated its Buy rating but revised its target price to $26 from $23 previously.

On August 09, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $28.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 22 ’24 when Curran Terrie sold 16,851 shares for $9.11 per share. The transaction valued at 153,513 led to the insider holds 410,784 shares of the business.

TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of PHAT for $29,999,994 on Jan 24 ’24. The 10% Owner now owns 3,755,583 shares after completing the transaction at $8.10 per share. On Jan 19 ’24, another insider, Henderson Molly, who serves as the CFO and CBO of the company, sold 6,307 shares for $7.75 each. As a result, the insider received 48,900 and left with 98,698 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 619.28M and an Enterprise Value of 376.91M. For the stock, the TTM Price-to-Sale (P/S) ratio is 911.60. Its current Enterprise Value per Revenue stands at 552.66 whereas that against EBITDA is -2.37.

Stock Price History:

Over the past 52 weeks, PHAT has reached a high of $17.02, while it has fallen to a 52-week low of $6.07. The 50-Day Moving Average of the stock is 8.68, while the 200-Day Moving Average is calculated to be 10.35.

Shares Statistics:

It appears that PHAT traded 845.33K shares on average per day over the past three months and 847.67k shares per day over the past ten days. A total of 57.97M shares are outstanding, with a floating share count of 26.04M. Insiders hold about 55.47% of the company’s shares, while institutions hold 44.62% stake in the company. Shares short for PHAT as of Mar 15, 2024 were 10.44M with a Short Ratio of 12.36, compared to 9.25M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.86% and a Short% of Float of 25.63%.

Earnings Estimates

As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.22 for the current quarter, with a high estimate of -$1.01 and a low estimate of -$1.48, while EPS last year was -$0.89. The consensus estimate for the next quarter is -$1.19, with high estimates of -$0.81 and low estimates of -$1.57.

Analysts are recommending an EPS of between -$3.34 and -$5.94 for the fiscal current year, implying an average EPS of -$4.56. EPS for the following year is -$3.21, with 7 analysts recommending between -$2.17 and -$4.15.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $53.9M, while the lowest revenue estimate was $34M, resulting in an average revenue estimate of $45.03M. In the same quarter a year ago, actual revenue was $682k, up 6,502.60% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $173.66M in the next fiscal year. The high estimate is $237.34M and the low estimate is $133.12M. The average revenue growth estimate for next year is up 285.70% from the average revenue estimate for this year.

Most Popular